EQS-News 137 0 Kommentare Epigenomics AG: Resignation of Supervisory Board Member Dr Heikki Lanckriet (PhD)

Für Sie zusammengefasst

Dr. Heikki Lanckriet resigns from Epigenomics AG's Supervisory Board.
The company will search for a suitable successor and arrange for their appointment.
The chairwoman of the Supervisory Board thanks Dr. Lanckriet for his commitment.

EQS-News: Epigenomics AG / Key word(s): Personnel
Epigenomics AG: Resignation of Supervisory Board Member Dr Heikki Lanckriet (PhD)

26.01.2024 / 13:16 CET/CEST
The issuer is solely responsible for the content of this announcement.

Epigenomics AG: Resignation of Supervisory Board Member Dr Heikki Lanckriet (PhD)

Berlin, Germany, January 26, 2024 – Dr Heikki Lanckriet (PhD) has informed the competent bodies of Epigenomics AG (Frankfurt General Standard: ECX, the “Company”) that he resigned as a member of the Company's Supervisory Board with effect as of 22 February 2024. The Supervisory Board will seek to find a suitable successor as member of the Company's Supervisory Board and arrange for his/her appointment by court order in accordance with the statutory provisions.

The chairwoman of the Supervisory Board, Dr Helge Lubenow, thanks Dr Heikki Lanckriet (PhD) for his commitment and dedication to the company and its employees.

Contact:
Company
Epigenomics AG, Bertha-Benz-Strasse 5, 10557 Berlin
Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, Email: contact@epigenomics.com

Investor Relations
IR.on AG, Frederic Hilke, Tel +49 221 9140 970, Email: ir@epigenomics.com

Note on forward-looking statements

This publication expressly or implicitly contains forward-looking statements concerning Epigenomics AG and its business. These statements involve certain known and unknown risks, uncertainties and other factors that may cause Epigenomics AG's actual results, financial condition and performance to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics makes this announcement as of the date of this release and does not intend to update any forward-looking statements contained herein as a result of new information or future events or otherwise.

26.01.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language:	English
Company:	Epigenomics AG
	Bertha-Benz-Straße 5
	10557 Berlin
	Germany
Phone:	+49 30 24345-0
Fax:	+49 30 24345-555
E-mail:	ir@epigenomics.com
Internet:	www.epigenomics.com
ISIN:	DE000A37FT41
WKN:	A37FT4
Listed:	Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID:	1824185